These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21862953)

  • 1. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
    Flaxel C; Schain MB; Hamon SC; Francis PJ
    Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration.
    Russo A; Costagliola C; Delcassi L; Romano MR; Semeraro F
    Br J Ophthalmol; 2013 Oct; 97(10):1273-6. PubMed ID: 23873901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
    Zweifel SA; Engelbert M; Khan S; Freund KB
    Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
    Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
    Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
    Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ
    Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes.
    Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
    Ophthalmic Surg Lasers Imaging; 2011; 42(6):468-73. PubMed ID: 21830747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
    Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
    Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
    Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
    Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P; Yue H; Wilson L
    Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy.
    Moshfeghi AA; Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
    Br J Ophthalmol; 2012 Oct; 96(10):1320-4. PubMed ID: 22895887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.